More than one reason to rethink the use of peptides in vaccine design

[1]  N. Grubhofer.  Vaccine Adjuvants Revisited , 2008 .

[2]  I. Bozic,et al.  Prediction of supertype-specific HLA class I binding peptides using support vector machines. , 2007, Journal of immunological methods.

[3]  Nicholas A Williamson,et al.  A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule , 2007, Nature Immunology.

[4]  J. Rossjohn,et al.  Tumors reveal their secrets to cytotoxic T cells , 2006, Proceedings of the National Academy of Sciences.

[5]  Anne M Evans,et al.  Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy , 2006, Proceedings of the National Academy of Sciences.

[6]  I. Toth,et al.  Particulate systems as adjuvants and carriers for peptide and protein antigens. , 2006, Current drug delivery.

[7]  P. Sutton,et al.  Saponin-adjuvanted particulate vaccines for clinical use. , 2006, Methods.

[8]  E. Unanue,et al.  Cutting Edge: Unique T Cells That Recognize Citrullinated Peptides Are a Feature of Protein Immunization1 , 2006, The Journal of Immunology.

[9]  J. Ingle,et al.  Peptide Vaccination of Patients With Metastatic Melanoma: Improved Clinical Outcome in Patients Demonstrating Effective Immunization , 2006, American journal of clinical oncology.

[10]  Federico Squassabia,et al.  Peptides and peptidomimetics in medicine, surgery and biotechnology. , 2006, Current medicinal chemistry.

[11]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[12]  V. Apostolopoulos,et al.  Design of peptide-based vaccines for cancer. , 2006, Current medicinal chemistry.

[13]  C. Klade,et al.  Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. , 2006, Vaccine.

[14]  Morten Nielsen,et al.  A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules , 2006, PLoS Comput. Biol..

[15]  N. Petrovsky.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. , 2006, Vaccine.

[16]  V. Engelhard,et al.  Post-translational modifications of naturally processed MHC-binding epitopes. , 2006, Current opinion in immunology.

[17]  A. Purcell,et al.  Optimisation of peptide-based cytotoxic T-cell determinants using non-natural amino acids , 2003, Letters in Peptide Science.

[18]  James McCluskey,et al.  Have we cut ourselves too short in mapping CTL epitopes? , 2006, Trends in immunology.

[19]  J. Schlom,et al.  Cancer vaccines: preclinical studies and novel strategies. , 2006, Advances in cancer research.

[20]  J. McCluskey,et al.  The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation , 2005, The Journal of experimental medicine.

[21]  R. Zurbriggen,et al.  Peptides delivered by immunostimulating reconstituted influenza virosomes , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[22]  Natalie A Borg,et al.  T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I–bound peptide , 2005, Nature Immunology.

[23]  K. Rock,et al.  Cross‐presentation: underlying mechanisms and role in immune surveillance , 2005, Immunological reviews.

[24]  J. Rossjohn,et al.  The insulin A-chain epitope recognized by human T cells is posttranslationally modified , 2005, The Journal of experimental medicine.

[25]  L. Brown,et al.  Lipid-based self-adjuvanting vaccines. , 2005, Current drug delivery.

[26]  J. McCluskey,et al.  T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo1 , 2005, The Journal of Immunology.

[27]  Natalie A Borg,et al.  CTL Recognition of a Bulged Viral Peptide Involves Biased TCR Selection1 , 2005, The Journal of Immunology.

[28]  Natalie A Borg,et al.  High Resolution Structures of Highly Bulged Viral Epitopes Bound to Major Histocompatibility Complex Class I , 2005, Journal of Biological Chemistry.

[29]  J. McCluskey,et al.  Qualitative and Quantitative Differences in Peptides Bound to HLA-B27 in the Presence of Mouse versus Human Tapasin Define a Role for Tapasin as a Size-Dependent Peptide Editor1 , 2005, The Journal of Immunology.

[30]  A. Purcell,et al.  Use of proteomics to define targets of T-cell immunity , 2005, Expert review of proteomics.

[31]  L. Brown,et al.  ISCOMTM‐based vaccines: The second decade , 2005, Immunology and cell biology.

[32]  Gina R Petroni,et al.  MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1 , 2005, The Journal of Immunology.

[33]  L. Zitvogel,et al.  Dendritic cell-derived exosomes as cell-free peptide-based vaccines. , 2005, Critical reviews in immunology.

[34]  S. Anderton.  Post-translational modifications of self antigens: implications for autoimmunity. , 2004, Current opinion in immunology.

[35]  M. Probst-Kepper,et al.  Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*35011 , 2004, The Journal of Immunology.

[36]  P. E. Van den Steen,et al.  Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. , 2004, Biochemistry.

[37]  L. K. Ely,et al.  Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion , 2004, The Journal of experimental medicine.

[38]  P. Kloetzel.  Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII , 2004, Nature Immunology.

[39]  A. Goldberg,et al.  Post-proteasomal antigen processing for major histocompatibility complex class I presentation , 2004, Nature Immunology.

[40]  H. Rammensee,et al.  The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Cell International.

[41]  T. Boon,et al.  An Antigenic Peptide Produced by Peptide Splicing in the Proteasome , 2004, Science.

[42]  Muthuraman Sathiamurthy,et al.  Toward a Definition of Self: Proteomic Evaluation of the Class I Peptide Repertoire1 , 2004, The Journal of Immunology.

[43]  P. Kloetzel,et al.  Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. , 2004, Current opinion in immunology.

[44]  Jonathan W. Yewdell,et al.  Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.

[45]  Hans-Georg Rammensee,et al.  The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[46]  J. McCluskey,et al.  Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. , 2003, Tissue antigens.

[47]  R. Tampé,et al.  Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  James McCluskey,et al.  A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition , 2003, The Journal of experimental medicine.

[49]  A. Sette,et al.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. , 2003, Current opinion in immunology.

[50]  Euijae Kim,et al.  A Single Polymorphic Residue Within the Peptide-Binding Cleft of MHC Class I Molecules Determines Spectrum of Tapasin Dependence , 2003, The Journal of Immunology.

[51]  L. K. Ely,et al.  Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[52]  D. Young,et al.  A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses1 , 2003, The Journal of Immunology.

[53]  D. Crommelin,et al.  Liposomes and ISCOMs. , 2003, Vaccine.

[54]  Euijae Kim,et al.  A Single Polymorphic Residue Within the Peptide-Binding Cleft of MHC Class I Molecules Determines Spectrum of Tapasin Dependence1 , 2003, The Journal of Immunology.

[55]  Peter J. S. Hutzler,et al.  Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells1 , 2002, The Journal of Immunology.

[56]  S. Muller,et al.  Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600-612 region of the HIV envelope gp41 glycoprotein. , 2002, Journal of molecular biology.

[57]  M. Buschle,et al.  Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration , 2002, Peptides.

[58]  M. del-Val,et al.  Multiple proteases process viral antigens for presentation by MHC class I molecules to CD8(+) T lymphocytes. , 2002, Molecular immunology.

[59]  G. Dranoff.  GM‐CSF‐based cancer vaccines , 2002, Immunological reviews.

[60]  L. Fugger,et al.  Predominant selection of T cells specific for the glycosylated collagen type II epitope (263–270) in humanized transgenic mice and in rheumatoid arthritis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Ulrich Steinhoff,et al.  Link between Organ-specific Antigen Processing by 20S Proteasomes and CD8+ T Cell–mediated Autoimmunity , 2002, The Journal of experimental medicine.

[62]  James McCluskey,et al.  Optimization of the MHC class I peptide cargo is dependent on tapasin. , 2002, Immunity.

[63]  P. Perlmutter,et al.  β-amino acids: Versatile peptidomimetics , 2002 .

[64]  P. Srivastava,et al.  Roles of heat-shock proteins in antigen presentation and cross-presentation. , 2002, Current opinion in immunology.

[65]  J. Strominger,et al.  Ligand Exchange of Major Histocompatibility Complex Class II Proteins Is Triggered by H-bond Donor Groups of Small Molecules* , 2002, The Journal of Biological Chemistry.

[66]  John Sidney,et al.  Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes That Are More Potent and Immunogenic than Wild-Type Peptide , 2001, The Journal of experimental medicine.

[67]  S. Groshen,et al.  Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Luft,et al.  Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation1 , 2001, The Journal of Immunology.

[69]  D. Rognan,et al.  β-Amino Acid Scan of a Class I Major Histocompatibility Complex-restricted Alloreactive T-cell Epitope* , 2001, The Journal of Biological Chemistry.

[70]  N. Viner,et al.  Cell Recognition of the Dominant I-A k – restricted Hen Egg Lysozyme Epitope : Critical Role for Asparagine Deamidation , 2001 .

[71]  R. Binder,et al.  Adjuvanticity of α2-Macroglobulin, an Independent Ligand for the Heat Shock Protein Receptor CD911 , 2001, The Journal of Immunology.

[72]  J. Hainfeld,et al.  Binding of Antigenic Peptide to the Endoplasmic Reticulum-resident Protein gp96/GRP94 Heat Shock Chaperone Occurs in Higher Order Complexes , 2001, The Journal of Biological Chemistry.

[73]  G W Butcher,et al.  Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. , 2001, Immunity.

[74]  L. Lybarger,et al.  Kb, Kd, and Ld Molecules Share Common Tapasin Dependencies as Determined Using a Novel Epitope Tag1 , 2000, The Journal of Immunology.

[75]  J. Briand,et al.  Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. , 2000, Journal of medicinal chemistry.

[76]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[77]  J. Rothman,et al.  Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways , 2000, The Journal of experimental medicine.

[78]  H. Rammensee,et al.  Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis , 2000, The Journal of experimental medicine.

[79]  T. Elliott,et al.  Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. , 2000, Tissue antigens.

[80]  A. Purcell,et al.  The peptide-loading complex and ligand selection during the assembly of HLA class I molecules. , 2000, Molecular immunology.

[81]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[82]  D. Jewell,et al.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope , 2000, Nature Medicine.

[83]  J. McCluskey,et al.  Endogenous and exogenous factors contributing to the surface expression of HLA B27 on mutant APC. , 2000, Human immunology.

[84]  D. Weber,et al.  Peptide exchange in MHC molecules , 1999, Immunological reviews.

[85]  A. Prescott,et al.  Membrane ruffling, macropinocytosis and antigen presentation in the absence of gelsolin in murine dendritic cells , 1999, European journal of immunology.

[86]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[87]  D. Wood,et al.  Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. , 1999, Biochemistry.

[88]  S Buus,et al.  Description and prediction of peptide-MHC binding: the 'human MHC project'. , 1999, Current opinion in immunology.

[89]  P. Srivastava,et al.  Calreticulin, a Peptide-binding Chaperone of the Endoplasmic Reticulum, Elicits Tumor- and Peptide-specific Immunity , 1999, The Journal of experimental medicine.

[90]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[91]  I. Wilson,et al.  Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. , 1999, Immunity.

[92]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[93]  A. D. De Groot,et al.  Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.

[94]  J. Miller,et al.  Cross-presentation: a general mechanism for CTL immunity and tolerance. , 1998, Immunology today.

[95]  P. Travers,et al.  T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen. , 1998, International immunology.

[96]  P. Cresswell,et al.  HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. , 1998, Immunity.

[97]  A. McMichael,et al.  TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide , 1998, Current Biology.

[98]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[99]  Pramod K. Srivastava,et al.  Heat Shock Protein–Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity , 1997, The Journal of experimental medicine.

[100]  P. Srivastava,et al.  Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.

[101]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[102]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[103]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.

[104]  J. McCluskey,et al.  CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. , 1996, Journal of immunology.

[105]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[106]  S. Burrows,et al.  Strategies involved in developing an effective vaccine for EBV-associated diseases. , 1996, Advances in cancer research.

[107]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[108]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[109]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[110]  P. L. Campbell,et al.  Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. , 1994, Journal of immunology.

[111]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[112]  C. Phornphutkul,et al.  Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. , 1994, International immunology.

[113]  R. Dwek,et al.  Recognition of carbohydrate by major histocompatibility complex class I- restricted, glycopeptide-specific cytotoxic T lymphocytes , 1994, The Journal of experimental medicine.

[114]  I. Toth.  A novel chemical approach to drug delivery: lipidic amino acid conjugates. , 1994, Journal of drug targeting.

[115]  William S. Lane,et al.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle , 1992, Nature.

[116]  C. Watts,et al.  Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments , 1990, Nature.

[117]  M. Kotb,et al.  Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M proteins. , 1989, Journal of immunology.